Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

Launched by OHSU KNIGHT CANCER INSTITUTE · Oct 4, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how the presence of circulating tumor DNA (ctDNA) in the blood can help doctors make better treatment decisions for patients with stage II and III rectal cancer. ctDNA is DNA that comes from the cancer cells and is found in the bloodstream. By measuring ctDNA levels before, during, and after treatment, researchers hope to learn if these levels can indicate how well the cancer is responding to standard therapies. This information could help improve treatment strategies that allow some patients to keep their organs instead of undergoing more invasive procedures.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of stage II or III rectal cancer. They should not have received any prior treatments for their cancer and must not have signs of cancer spreading to other parts of the body. Participants will be asked to provide consent and will undergo blood tests at various points during the study. This research is currently recruiting, and all genders are welcome to apply. If you or a loved one fits the criteria, this could be an opportunity to contribute to important findings in rectal cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant must provide written informed consent before any study-specific procedures or interventions are performed
• • Participants aged \>= 18 years
• * Pathologically-confirmed stage II or III primary adenocarcinoma of the rectum:
• • T3N0M0 - T4bN2M0
• Exclusion Criteria:
• • Has radiologic evidence of distant metastases at the time of screening/enrollment
• • Has received prior treatment for their rectal adenocarcinoma
• • Requires or has received blood transfusion within 1 month of study enrollment